MEDAREX INC
10-Q, EX-27.1, 2000-11-08
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: MEDAREX INC, 10-Q, 2000-11-08
Next: AMERICAN MEDICAL TECHNOLOGIES INC/DE, 10-Q, 2000-11-08



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE IN SUCH STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               SEP-30-2000
<CASH>                                          68,336
<SECURITIES>                                   297,734
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               384,724
<PP&E>                                           9,865
<DEPRECIATION>                                 (5,473)
<TOTAL-ASSETS>                                 484,445
<CURRENT-LIABILITIES>                           34,724
<BONDS>                                              0
                                0
                                          0
<COMMON>                                           734
<OTHER-SE>                                     426,824
<TOTAL-LIABILITY-AND-EQUITY>                   484,445
<SALES>                                            150
<TOTAL-REVENUES>                                10,916
<CGS>                                               83
<TOTAL-COSTS>                                   34,978
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   3
<INCOME-PRETAX>                                (8,269)
<INCOME-TAX>                                     4,365
<INCOME-CONTINUING>                           (12,634)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (12,634)
<EPS-BASIC>                                     (0.18)
<EPS-DILUTED>                                   (0.18)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission